Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer
12 mai 2022 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022
04 mai 2022 08h00 HE
|
Morphic Therapeutic
Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Described new understanding of α4β7-expressing immune cells and MORF-057 dose response in oral presentation at ECCO...
Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development
06 avr. 2022 08h00 HE
|
Morphic Therapeutic
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron Pelta promoted to Senior Vice President, Business and Corporate Development;...
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
30 mars 2022 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis
25 mars 2022 08h00 HE
|
Morphic Therapeutic
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of MORF-057 expected to begin mid-year 2022 WALTHAM,...
Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference
04 mars 2022 09h05 HE
|
Morphic Therapeutic
WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021
24 févr. 2022 07h30 HE
|
Morphic Therapeutic
Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis scheduled to begin 1Q22; Phase 2b to commence mid-year Presented preclinical data from αvβ8 program at...
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
22 févr. 2022 08h00 HE
|
Morphic Therapeutic
New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support ongoing clinical development program in IBD WALTHAM, Mass., Feb. 22, 2022 ...
Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Participation in Upcoming Investor Conferences
16 nov. 2021 09h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...